Hyperphosphatemia Treatment Global Market Report 2024

Hyperphosphatemia treatment involves a class of drugs designed to enhance renal excretion for managing patients with elevated levels of phosphates. The most effective method is through volume replenishment using saline and forced diuresis with a loop diuretic such as furosemide or bumetanide.

The primary products in the hyperphosphatemia treatment market include sevelamer, calcium-based phosphate binders, iron-based phosphate binders, lanthanum carbonate, and others. The sevelamer market comprises sales of sevelamer products by entities (organizations, partnerships, and sole traders). Sevelamer is a phosphate-binding medication used to treat hyperphosphatemia in patients with chronic kidney diseases. The distribution of hyperphosphatemia treatment occurs through various channels, including hospital pharmacies, retail pharmacies, and online stores. In terms of dosage form, it is segmented into capsules, tablets, and syrups.

The hyperphosphatemia treatment market research report is one of a series of new reports that provides hyperphosphatemia treatment market statistics, including hyperphosphatemia treatment industry global market size, regional shares, competitors with a hyperphosphatemia treatment market share, detailed hyperphosphatemia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hyperphosphatemia treatment industry. This hyperphosphatemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hyperphosphatemia treatment market size has grown rapidly in recent years. It will grow from $4.1 billion in 2023 to $4.61 billion in 2024 at a compound annual growth rate (CAGR) of 12.6%. The growth during the historical period can be attributed to factors such as an increased incidence of chronic kidney disease (CKD), the growth of the aging population, a high prevalence of diabetes and hypertension, the expansion of the dialysis patient population, and advances in medical research and the diagnosis of hyperphosphatemia.

The hyperphosphatemia treatment market size is expected to see rapid growth in the next few years. It will grow to $7.54 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The anticipated growth in the forecast period can be attributed to factors such as the rise in lifestyle-related diseases contributing to hyperphosphatemia, continued growth in aging demographics, increasing awareness and diagnosis of hyperphosphatemia, expansion of emerging markets with a high disease burden, and a higher prescription share of calcium-based phosphate binders in emerging countries. Noteworthy trends expected in the forecast period encompass advancements in hyperphosphatemia treatment technologies, the integration of telehealth and remote patient monitoring, collaborations and partnerships for research and development, a focus on patient education and lifestyle management in hyperphosphatemia, and the development of novel phosphate binders and therapies.

The growth of the hyperphosphatemia treatment market is being fueled by the increasing prevalence of chronic diseases among patients, which require long-term care. Chronic diseases, including cardiovascular diseases, chronic kidney disease, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer, contribute to a significant portion of global deaths, with 74% attributed to non-communicable diseases (NCDs) or chronic diseases, as reported by the World Health Organization in September 2023. Notably, kidney diseases are on the rise, with untreated kidney failure claiming the lives of approximately 1 million individuals each year, according to SingleCare Services LLC in February 2023. The escalating cases of hyperphosphatemia in patients with end-stage renal disease (ESRD) are driving the demand for hyperphosphatemia treatment drugs.

The hyperphosphatemia treatment market is anticipated to experience growth due to the increasing adoption of dietary modifications. Intentional changes in eating habits or diet adjustments play a significant role in managing hyperphosphatemia, offering control over phosphate levels, preventing complications, reducing the need for medication, promoting overall health, and enhancing the quality of life. For example, in June 2022, the Food Standards Agency (FSA) in the UK reported that eight out of ten people have made changes to their eating habits over the past 12 months. The survey revealed that 23% of Scottish adults acknowledged their diet had worsened during the epidemic, and 75% recognized the need for significant dietary adjustments to improve their health. Thus, the increasing trend of dietary modifications is a driving force for the hyperphosphatemia treatment market.

A key trend in the hyperphosphatemia treatment market is the surge in research and development activities. Companies in this sector are intensively focused on R&D to develop innovative therapies for renal diseases and associated chronic conditions. For instance, in May 2021, Shanghai-based biopharmaceutical company Alebund Pharmaceuticals secured $60 million in a Series B funding round, aimed at accelerating the development of innovative drugs and solutions for renal diseases, including hyperphosphatemia.

Major companies in the hyperphosphatemia treatment market are concentrating on the development of innovative products, such as Xphozah, to drive market revenues. Xphozah, designed to treat hyperphosphatemia, addresses the excessive phosphorus causing calcium removal from bones and various body parts. In October 2023, Ardelyx Inc., a US-based biopharmaceutical company, received FDA approval for Xphozah. This approval is for the treatment of hyperphosphatemia in patients unresponsive or intolerant to current standard-of-care phosphate binder therapies.

In May 2023, South Africa-based healthcare services group Life Healthcare Group Holdings Limited acquired Fresenius Medical Care AG and Co. KGaA for an undisclosed amount. This strategic acquisition enhances Life Healthcare's offerings in acute and ongoing renal dialysis treatments in South Africa. With the acquisition, Life Healthcare aims to play a vital role in ensuring the continuity of existing patient care plans. Fresenius Medical Care AG and Co. KGaA, a Germany-based company manufacturing hyperphosphatemia treatment drugs, is now part of Life Healthcare Group Holdings Limited.

Major companies operating in the in the hyperphosphatemia treatment market report are Sanofi SA, Akebia Therapeutics Inc., AMAG Pharmaceuticals Inc., Ardelyx Inc., Astellas Pharma Inc., Fresenius Medical Care AG & Co. KGaA, Keryx Biopharmaceuticals Inc., Lupin Limited, Shire plc, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., Unicycive Therapeutics Inc., Vifor Pharma Management Ltd., Zeria Pharmaceutical Co. Ltd., Abbott Laboratories, Amgen Inc., AstraZeneca plc, B. Braun Melsungen AG, Baxter International Inc., Beckman Coulter Inc., Cleveland Clinic, DaVita Inc., Encompass Health Corporation, FMC Corporation, Hospital Corporation of America Healthcare Inc., Kyowa Kirin Pharmaceuticals Co. Ltd., Mayo Clinic, Medtronic plc, OPKO Health Inc., Roche Diagnostics Corporation, Siemens Healthineers AG, Sysmex Corporation, Tenet Healthcare Corporation, Thermo Fisher Scientific Inc., UnitedHealth Group Inc.

North America was the largest region in the hyperphosphatemia treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperphosphatemia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hyperphosphatemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The hyperphosphatemia treatment market includes revenues earned by lowering the phosphate load and maintaining serum phosphorus levels within the normal range. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.